SplitJun 26, 2026, 09:26 AM
Quince Therapeutics Announces 1-for-20 Reverse Stock Split
AI Summary
Quince Therapeutics, Inc. announced the implementation of a 1-for-20 reverse stock split, previously approved by stockholders. The Certificate of Amendment was filed on June 26, 2026, becoming effective at 11:59 pm ET on June 29, 2026. The company's common stock will commence trading on a split-adjusted basis on the Nasdaq Global Select Market at market open on June 30, 2026, under a new CUSIP number while retaining the QNCX ticker symbol. The split will reduce the number of outstanding shares from approximately 19.56 million to 0.98 million, with fractional shares being paid in cash.
Key Highlights
- Board approved a 1-for-20 reverse stock split.
- Certificate of Amendment filed on June 26, 2026, effective June 29, 2026, at 11:59 pm ET.
- Shares will begin trading on a split-adjusted basis on Nasdaq on June 30, 2026.
- Pre-split: 19,559,257 shares outstanding; Post-split: approximately 977,963 shares outstanding.
- New CUSIP number 22053A305 effective June 30, 2026; ticker symbol QNCX remains unchanged.
- Fractional shares will be paid in cash.
- All outstanding stock options and warrants will be proportionally adjusted.
Price Impact
More from QNCX